Qiagen (NYSE:QGEN): Reassessing Valuation After Strong Q3 2025 Beat and Upgraded Growth Outlook

Qiagen (NYSE:QGEN) just delivered a third quarter 2025 update that checked two big boxes for investors: earnings and revenue both climbed year over year, and management backed that up with higher full year growth guidance.

See our latest analysis for Qiagen.

That upbeat earnings story has helped the stock regain some traction, with a roughly 6.6% 1 month share price return and an 8.98% 1 year total shareholder return suggesting momentum is slowly rebuilding after a tougher multi year stretch.

If Qiagen’s update has you looking more broadly at healthcare names riding similar trends, this could be a good moment to explore healthcare stocks.

But with the share price already rebounding and analysts only seeing modest upside to their targets, is Qiagen still trading at a meaningful discount, or is the market already pricing in its next leg of growth?

Most Popular Narrative Narrative: 7.3% Undervalued

Qiagen’s most followed valuation narrative pegs fair value slightly above the recent 47.08 dollar close, implying a modest disconnect between price and fundamentals.

The analysts have a consensus price target of 52.392 dollar for Qiagen based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of 60.0 dollar, and the most bearish reporting a price target of just 45.0 dollar.

Read the complete narrative.

Curious how revenue trends, changes in margins, and only modest share dilution can still justify a higher value using a disciplined discount rate? The full narrative reveals the earnings path and valuation math that tie those moving parts together.

Result: Fair Value of $50.79 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, prolonged weakness in life sciences funding, or intensifying competition in digital PCR and syndromic testing, could easily derail that gradual improvement story.

Find out about the key risks to this Qiagen narrative.

Build Your Own Qiagen Narrative

If you view the outlook differently, or simply want to dig into the numbers yourself, you can build a personalized story in minutes: Do it your way.

A great starting point for your Qiagen research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Qiagen might fit your strategy, but you will miss some standout opportunities if you stop here, so use the Simply Wall St Screener to uncover more potential winners.

• Capture mispriced opportunities early by reviewing these 909 undervalued stocks based on cash flows that could offer stronger upside than widely followed large caps.
• Tap into market changing innovation by scanning these 26 AI penny stocks where real revenue growth meets powerful technology trends.
• Strengthen your income stream by filtering for these 15 dividend stocks with yields > 3% that can support long term, compounding returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com